Intriguingly, even with an intact TP53 response, the ONECUT3-driven phenotypes of aberrant karyotypes and drug resistance persisted across multiple cell models, suggesting that ONECUT3 might be a potential therapeutic target for patients with MDS, particularly those with WT TP53. This evidence concerns the gene TP53 and myelodysplastic syndrome.